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Background:  A   diagnosis   of   malignant   hyperthermia   susceptibility  
(MHS)  by  in  vitro  contraction  testing  can  often  only  be  performed  at  
specialized   laboratories   far   away   from   where   the   patients   live.  
Therefore,  we  have  designed  a  protocol   for  genetic   screening  of   the  
RYR1-­‐‑cDNA  and  for  functional  testing  of  newly  identified  ryanodine  
receptor   1   (RYR1)   gene   variants   in   B   lymphocytes   isolated   from  
peripheral  blood  samples  drawn  at  the  local  primary  care  centres.  
    
Methods:  B   lymphocytes  were   isolated   for   the   extraction   of   RYR1-­‐‑
mRNA  and  genomic  DNA  and  for  establishment  of   lymphoblastoid  
B  cell  lines  in  five  patients  carrying  yet  unclassified  mutations  in  the  
RYR1.   The   B   lymphoblastoid   cell   lines   were   used   to   study   resting  
cytoplasmic   calcium   concentration,   the   peak   calcium   transient  
induced   by   the   sarco(endo)plasmic   reticulum   CaATPase   inhibitor  
thapsigargin  and  the  dose  dependent  calcium  release  induced  by  the  
ryanodine  receptor  agonist  4-­‐‑chloro-­‐‑m-­‐‑cresol.    
  
Results:  It  was  possible  to  extract  mRNA  for  cDNA  synthesis  and  to  
create   B   lymphocyte   clones   from   all   samples.  All   B   lymphoblastoid  
cell   lines   carrying   RYR1   candidate   mutations   showed   significantly  
elevated  resting  cytoplasmic  calcium  levels  as  well  as  a  shift  to  lower  
concentrations   of   4-­‐‑chloro-­‐‑m-­‐‑cresol   inducing   calcium   release  
compared  to  controls.  
  
Conclusions:   Peripheral   blood   samples   are   stable   regarding   RNA  
and  DNA  extraction  and  establishment  of  lymphoblastoid  B  cell  lines  
after   transportation   at   ambient   temperature   over   large   distances   by  
ordinary   mail.   Functional   tests   on   B   cells   harbouring   the   newly  
identified   amino   acid   substitutions   indicate   that   they   alter  
intracellular   Ca2+   homeostasis   and   are   most   likely   causative   of  
malignant  hyperthermia  (MH).    
In   individuals   who   are   genetically   predisposed   to   Malignant  
Hyperthermia   (MHS;   OMIM   *145600),   halogenated   anaesthetics  
and/or   suxamethonium   can   induce   a   severe   decompensation   of  
muscle   calcium   homeostasis   leading   to   a   life   threatening   crisis  
including   hyperthermia,   tachycardia,   coagulation   disturbances,  
generalised   muscle   rigidity,   oliguria   and   eventually   death   (1).   The  
diagnosis  of  MHS  is  traditionally  made  by  an  in  vitro  contraction  test  
(IVCT).   This   investigation   is   highly   invasive   requiring   an   open  
muscle  biopsy   from  m.  quadriceps  and  specialized   testing  equipment  
(2).  
      
The   clinical   presentation   of   Central   Core   Disease   (CCD;   OMIM  
*117000)   is   highly   variable   and   symptoms  may   vary   from   clinically  
very   mild   to   severe   congenital   myopathy   with   hypotonia,   skeletal  
abnormalities  and  scoliosis  (3,  4).  
  
The   ryanodine   receptor   1   (RYR1)   is   encoded   by   the   RYR1   gene  
located   on   chromosome   19q13.1.   The   gene   comprises   159,000   base  
pairs  which   are   distributed   over   106   exons.   The  RYR1-­‐‑cDNA  has   a  
length  of  15,117  kb  and  encodes  a  protein  monomer  of  5,038  amino  
acids  (5,  6).  More  than  200  sequence  variants  in  the  RYR1  gene  have  
been   identified   to   date   and   linked   to   MHS,   CCD   other  
neuromuscular   disorders,   yet   the   functional   impact   of   only   a  
minority   of   these   amino   acid   substitutions   have   been   elucidated   to  
date  (www.emhg.org).  The  vast  majority  of  these  variants  have  been  
found   in   individual   patients   and   their   families   and   only   a   few  
recurrent   variants   account   for   less   than   10   %   of   the  MHS   subjects,  
each  (5,  6).    
  
Ca2+  is  a  second  messenger  in  skeletal  muscle  cells.  It  is  stored  in  the  
sarcoplasmic   reticulum,   an   organelle   whose   function   is   intimately  
linked  to  regulating  the  myoplasmic  Ca2+  concentration  (7-­‐‑11)  and  is  
released   via   a   process   known   as   excitation-­‐‑contraction   coupling  
(ECC).   When   the   dihydropyridine   receptor   (DHPR),   the   voltage  
sensor  on  the  plasmalemma,  senses  a  change  in  membrane  potential,  
it  undergoes  a  conformational  change  and  directly  interacts  with  the  
ryanodine   receptor   1   Ca2+   channel,   causing   it   to   open.   DHPR   and  
RYR1   form   highly   organized   structures   on   their   respective  
membranes:   four   DHPR   units   on   the   transverse   tubular  membrane  
face   corresponding   RYR1   tetramers   located   on   the   junctional   face  
membrane   of   the   terminal   cisternae   (12).   Because   Ca2+   can   act   as   a  
second   messenger   in   many   biological   functions,   its   intracellular  
concentration  is  tightly  regulated  and  maintained  in  a  typical  resting  
mammalian  cell  at  about  60-­‐‑120  nM,  while  the  extracellular  free  Ca2+  
concentration  is  about  2  mM  (8,  9).  Any  alteration  of  Ca2+  homeostasis  
can  affect  the  function  of  cells.  In  muscle  cells,  genetic  disturbances  of  
Ca2+  handling  result  in  a  variety  of  neuromuscular  disorders  such  as  
MHS,  CCD,  some  forms  of  Multiminicore  Disease  and  Centronuclear  
Myopathy,  and  Brody’s  disease  (4,  6,  13).  
  
Although  the  RYR1   is  mainly  expressed   in  striated  muscle  cells   it   is  
now  well   established   that   B   lymphocytes   also   express   this   calcium  
channel  (14,  15).  
    
The  aim  of  the  present  study  was  to  develop  an  alternative  protocol  
for   diagnostic   studies   on   MH   individuals   by   transporting   blood  
samples   instead  of   the  patients   themselves   to   the  specialized  testing  
centre.   This   increases   the   opportunity   of   MHS   diagnosis   even   if   a  
patient’s  health  service  provider  is  far  away  from  the  MH  laboratory.  
We   designed   a   simple   and   practical   protocol   for   the   collection   of  
blood  samples  to  be  drawn  at  the  patients’  local  primary  care  centres.  
Three  venous  peripheral  blood  samples  of  5  ml  each  were  collected  in  
different  test  tubes  for  mRNA  and  genomic  DNA  extraction  and  for  
establishment   of   B   lymphoblastoid   cell   lines.  Genetic   screening   and  
functional  studies  were  successfully  performed  on  these  samples.  




With  Regional  Ethics  Committee  approval   the  patients  participating  
in   the   study  were   informed  by   telephone  and  also   signed  a  written  
consent   to   the   study.   All   patients   carried   one   candidate   RYR1  
mutation   each;   patient   1:   p.Glu1058Lys,   patient   2:   p.Arg1679His,  
patient   3:   p.His382Asn,   patient   4:   p.Lys1393Arg   and   patient   5:  
p.Arg2508Gly.   These   are   the   patients   from   a   cohort   of   15  
Scandinavian  MHS  patients,  who  where  screened  for  the  RYR1   total  
coding  region  in  our  previous  study  (16),  and  found  to  carry  a  novel  
or  yet  unclassified  sequence  variant.    
  
Details   of   the   clinical  presentation  of   the  patients  with   the   reported  
RYR1  amino  acid  substitutions  are  given  in  Table  1  and  in  Appendix  
1.  
  
For  patients  1-­‐‑4,  the  MH  rank  was  assessed.  The  MH  rank  describes  
the  qualitative  likelihood,  from  1  =  almost  never  to  6  =  almost  certain,  
that   an   adverse   anaesthetic   event   represents   MH.   This   clinical  
grading  scale  requires  the  anaesthesiologist  to  judge  whether  specific  
clinical   signs   are   appropriate   for   the   patient’s   medical   condition,  
anaesthetic  technique  or  surgical  procedure  (17).  The  MH  rank  scores  
are   presented   in   Table   1   and   in   Appendix   1.   Patient   5   has   an  
established  CCD  diagnosis  and  his  main  symptoms  are  scoliosis  and  
muscle   weakness   in   the   lower   extremities.   A   microscopic  




Patients  1-­‐‑4  had  suffered  serious  MH  clinical  reactions  and  thereafter  
been  tested  by  IVCT  and  classified  as  MHS.  The  CCD  patient  (patient  
5)   was   tested   by   the   IVCT   as   part   of   standard   diagnostic  
investigations   in   order   to   establish   his   diagnosis   and   was   also  
classified   as   MHS.   All   IVCTs   were   carried   out   at   the   National  
Swedish   Malignant   Hyperthermia   Laboratory   of   Lund   University  
Hospital  according  to  the  European  Malignant  Hyperthermia  Group  





The   patients   were   provided   with   written   information   about   the  
sampling  process.  Peripheral  venous  blood   samples  were  drawn  by  
the   local   family  doctor   in   an  EDTA   tube,   a   PAXgene   tube   and   in   a  
heparin   tube.   The   tubes   were   sent   by   normal  mail   without   further  
handling   or   cooling   to   the   laboratory   in   Würzburg,   Germany,   a  
distance   up   to   2000   km   and   a   transportation   time   up   to   six   days.  
Because   PAXgene   tubes   are   not   normally   available   at   Swedish  




Total  RNA  was   extracted   from   the  PAXgene   tubes   according   to   the  
manufacturer’s   instructions   and   genomic   DNA   of   leukocytes   from  
the  EDTA  tubes  according  to  standard  protocols.  First  strand  cDNA  
was   synthesized   using   SuperScriptTM   II   (Invitrogen,   Carlsbad,  
California)   according   to   the  manufacturer’s   instructions.  Due   to   the  
size   of   the   RYR1-­‐‑mRNA,   the   first   cDNA   strand   was   synthesized  
using  three  mixes  of  specific  primers.  The  resulting  first  strands  were  
then  amplified   in   500-­‐‑700  base  pairs  overlapping   fragments  using  a  
second   set   of   primers   (primers   sequences   are   available   from   the  
authors  on  request).  Sequencing  was  performed  by  the  BigDye  1.1  kit  
on  an  ABI  3130  XL   (Applied  Biosystems,  Darmstadt,  Germany).  All  
cDNA   sequence   variants   leading   to   amino   acid   substitutions   were  
confirmed  on  genomic  DNA  from  the  same  patient  (16,  18).  
  
Establishment  of  EBV  immortalized  B  lymphoblastoid  cell  lines  
  
B  lymphocytes  were  isolated  from  the  blood  collected  in  the  heparin  
tubes   and   transformed   by   Epstein   Barr   virus   (EBV),   as   previously  




Changes   in   the   intracellular   Ca2+   concentration   ([Ca2+]i)   of      the   B  
lymphoblastoid  cells  from  patients  carrying  the  candidate  mutations  
and  from  healthy  controls  were  assessed  as  previously  described  (14,  
18),  after   loading  cells  with  the  fluorescent  Ca2+   indicator  fura-­‐‑2/AM  
(5   µμM   final   concentration).   Experiments   were   carried   out   on   cell  
populations   in   a   thermostatted   LS-­‐‑50   Perkin   Elmer  
spectrofluorimeter   equipped   with   a   magnetic   stirrer.   The   peak  
increase   of   the   Ca2+   transient   obtained   after   addition   of   a   given  
concentration   of   4-­‐‑chloro-­‐‑m-­‐‑cresol   on   the   linear   part   of   the   fura-­‐‑2  
calcium  sensitive  curve  was  expressed  as  percentage  of  the  peak  Ca2+  
released  by  maximal   concentrations   (1000  µμM)  of   4-­‐‑chloro-­‐‑m-­‐‑cresol.  
In   order   to   assess   if   the   RYR1   mutation   affected   the   size   of   the  
intracellular   Ca2+   stores,   the   area   under   the   curve   (AUC)   obtained  
after   addition   of   400   nM   thapsigargin,   which   represents   the   total  
amount   of   Ca2+   present   in   the   rapidly   releasable   intracellular   Ca2+  




Statistical   analysis   was   performed   using   Student'ʹs   t   test   for   paired  
samples   or   ANOVA  when  more   than   two   groups   were   compared.  
Origin   computer   program   (Microcal   Software,   Inc.,   Northampton,  
MA,  USA)  was  used  for  statistical  analysis  and  dose  response  curve  
generation.  The  area  under  curve  (AUC)  values  were  calculated  from  
the   dose   response   curves   whereas   the   EC50   and   Rmax   values   were  
calculated  from  sigmoidal  curve  fitting  of  all  data  points.  Results  are  
expressed  as  mean  value  (±  SEM)  of  n  results,  where  n  stands  for  the  




Following   the   sampling   protocol   as   outlined   in   Materials   and  
Methods,   peripheral   blood   samples   proved   to   be   sufficiently   stable  
during  transportation  by  ordinary  mail  at  ambient  temperatures  over  
a   period   of   up   to   six   days   for   RNA   and   DNA   extraction   and  
establishment   of   lymphoblastoid   B   cell   lines.   Genetic   screening   for  
the  presence  of  RYR1  mutations  (16)  and  calcium  measurements  on  B  
lymphocytes  could  successfully  be  performed  on  these  samples.    
  
We   first   examined   the   resting   [Ca2+]i   of   the  B   lymphocytes   carrying  
the  newly  identified  sequence  variants  and  compared  it  to  the  resting  
[Ca2+]i   of   healthy   controls   (Figure   2).   All   cell   lines   carrying   a  
candidate   mutation   showed   statistically   significant   higher   resting  
[Ca2+]i   compared   to   cell   lines   from   healthy   controls.   On   the   other  
hand,   the   AUC   calculations   of   the   Ca2+   transient   obtained   after  
stimulating   the   B   lymphocytes   with   400   nM   thapsigargin   were   all  
within   the   same   range,   irrespective   of   whether   cells   were   obtained  
from   controls   or   from   individuals   carrying   the   indicated   RYR1  
candidate  mutations  (Figure  2).  These  results   imply  that  none  of  the  
mutations  affect  the  size  of  the  intracellular  Ca2+  stores  in  a  way  that  
could   not   be   compensated   by   the   cells.  Nevertheless,   all   the   amino  
acid  substitutions  affect  Ca2+  homeostasis  since  they  cause  a  small  but  
significant   increase   in   the   resting   Ca2+,   a   result   which   has   been  
previously  shown  for  B  lymphocytes  from  individuals  with  the  MHS  
phenotype  (15,  19-­‐‑21).  
    
We   next   determined  whether   the   newly   identified  mutations   affect  
the  sensitivity  of  Ca2+  release  induced  by  the  RYR1  agonist  4-­‐‑chloro-­‐‑
m-­‐‑cresol.  Figure  3,  panel  A  shows  the  typical  increase  in  cytoplasmic  
[Ca2+]i  obtained  in  control  cells  after  the  addition  of  600  µμM  4-­‐‑chloro-­‐‑
m-­‐‑cresol.   The   trace,   which   represents   the   mean   change   in  
fluorescence  of  1.5x106  cells,  shows  that  addition  of  the  RYR1  agonist  
is  accompanied  by  a  transient  increase  in  the  340/380  nm  fluorescent  
ratio,   which   returns   to   resting   levels   within   about   10   minutes.  We  
then   constructed   4-­‐‑chloro-­‐‑m-­‐‑cresol   dose   response   curves   by  
calculating   the   peak   Ca2+   released   by   4-­‐‑chloro-­‐‑m-­‐‑cresol   in   a  
population   (1.5x106   cells)  of   fura-­‐‑2   loaded  B-­‐‑cells   as  a  percentage  of  
the  maximum  amount  which  could  be  released  by  1000  µμM  4-­‐‑chloro-­‐‑
m-­‐‑cresol.   Results   are   given   as   means   ±   SEM.   The   dose   response  
curves   from   the   cell   lines   carrying   each   of   the   candidate  mutations  
showed  a  significant  shift  to  the  left  compared  to  the  curves  from  the  
cell   lines  from  healthy  controls.  Table  2  shows  the  EC50  values  for  4-­‐‑




In   the   present   study   we   have   used   a   practical   protocol   to   draw  
peripheral   blood   samples   from   MHS   individuals   at   their   local  
primary   care   centres   in   order   to   screen   and   identify  RYR1   variants  
and   to   perform   functional   tests   on   the   newly   identified   candidate  
mutations.  Blood  samples  were  sent  by  ordinary  mail  from  different  
locations   in  Sweden   to   the   laboratory   in  Würzburg,  Germany,   from  
September   to   January  which   is  autumn  and  wintertime   in  Northern  
Europe.  Thus,   the  samples  were  not  exposed   to  extreme  heat  which  
could  have  compromised  their  viability.  
  
Four   of   the   substitutions   described   in   the   present   report   were  
identified   in  MHS  patients  who  had  developed   life   threatening  MH  
reactions   during   anaesthesia   (p.Glu1058Lys,   p.Arg1679His,  
p.His382Asn,  p.Lys1393Arg).  None  of   these   substitutions  have  been  
reported   in   former   patients.   The   fifth   substitution   (p.Arg2508Gly)  
occurring  in  the  CCD  patient,  has  been  identified  before  in  a  cohort  of  
CCD  patients  from  Japan  (22).    
  
Patient  1  (p.Glu1058Lys)  has  a  certain  suspicion  of  muscular  disease  
(see   Appendix   1)   but   despite   large   investigations   a   definitive  
diagnosis  has  not  been  found.  Patients  with  myotonic  muscle  disease  
can   react   especially   to   suxamethone   (23)   and   thus   one   could   argue  
the   reaction   she   experienced  was   not   true  malignant   hyperthermia.  
However  the  clinical  reaction  scores  high  on  the  larach  scale  and  had  
symptoms   that   are   not   first   line   in   myotonic   patients   reacting   to  
suxamethone  and  inhalational  anesthetics.  
  
In  our  previous  study  (16)  the  substitution  p.Arg1679His  was  found  
in  1  of  150  healthy  anonymised  German  subjects  and  p.Lys1393Arg  in  
1   of   100   Swedish   subjects   leaving   the   possibility   of   rare  
polymorphisms.   However,   the   population   prevalence   of   a   genetic  
MH   disposition   has   never   been   studied.   Therefore,   these   control  
subjects   could   likewise   be   as   yet   unidentified   MH   carriers.   Ideal  
controls   would   be   individuals   with   known   IVCT   status   MHN   of  
course.  
  
Following  the  report  by  Sei  et  al  (14)  that  also  B  lymphocytes  express  
a  functional  type  1  RYR,  we  and  others  have  exploited  such  a  system  
to   investigate   the   functional   effect   of   candidate  mutations   linked   to  
MHS   and   CCD   phenotypes   (15,   18-­‐‑20,   21-­‐‑22,   24-­‐‑27).   These   studies  
have   revealed   that   most   MH   causing   mutations   disturb   normal  
calcium  homeostasis  by  (i)  shifting  the  sensitivity  of  pharmacological  
RYR1  activation   to   lower   agonist   concentrations   and   (ii)   by   causing  
an   increase   in   the   resting   [Ca2+]i   (15,   20-­‐‑21,   24).   Overall,   the   results  
compared  well   to   the   IVCT  data  of   the   same  subjects.  Likewise,   the  
results   of   the   present   study   demonstrate   a   significant   alteration   of  
intracellular  Ca2+  handling  for  all  five  candidate  mutations.  
  
The   magnitude   of   the   disturbance   of   the   intra   cellular   Ca2+  
homeostasis  in  our  study  is  in  the  same  range  and  can  be  compared  
to  similar  measurements  in  other  studies  (28).  
  
Assessing  Ca2+  homeostasis  in  the  immortalized  B  lymphocyte  system  
offers   several   advantages   such   as:   (i)   cells   can   be   grown   in   large  
numbers,   (ii)   are   easy   to   handle   and   (iii)   can   be   assayed   using   a  
simple  methodology  such  as  fluorimetric  analysis  of  cells  loaded  with  
the   fluorescent   Ca2+   indicator   fura-­‐‑2   and   stimulated  with   the   RYR1  
agonist   4-­‐‑chloro-­‐‑m-­‐‑cresol.   In   this   context,   it   should   be   emphasized  
that  this  system  is  only  useful  for  assessing  RYR1  mutations  and  not,  
for  example,  mutations   found   in   the  alpha-­‐‑1   subunit  gene  encoding  
the   DHPR,  which   has   been   found   to   harbour  mutations   in   a   small  
number  of  MHS  families  (29)  since  this  isoform  of  the  voltage  sensor  
is  probably  not  expressed  in  B  lymphocytes.    
  
We  conclude  from  our  results  that  the  RYR1  amino  acid  substitutions  
studied  are  highly  likely  to  be  associated  with  the  MH  status  in  these  
patients.   According   to   the   guidelines   of   the   EMHG   (30)   RYR1  
mutations  should  only  be  regarded  as  causative  of  MH  if   functional  
tests   have   been   performed   on   tissues   from   at   least   two   unrelated  
individuals  carrying  the  same  candidate  mutation.  This,  however,   is  
impeded  by  the  rareness  of  most  RYR1  mutations.  
  
30  %   of   the  MH   families  will   not   demonstrate   linkage   to   the  RYR1  
and  thus  will  not  benefit  from  the  method  of  testing  the  ryanodine  1  
receptor  in  the  B  lymphocytes  (5,  16).  
  
We   propose   our   protocol   as   a   complementary   approach   for   the  
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